STAT+: Novo Nordisk’s obesity pill bests Wegovy in early trial

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, people taking Novo Nordisk’s injectable drug Wegovy lost about 6% of their body weight and the placebo group lost around 1%.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Continue to STAT+ to read the full story…

Read Original Article: STAT+: Novo Nordisk’s obesity pill bests Wegovy in early trial »